Search the Newsreel

Xos Inc (XOS) Cash Flow

This article provides a detailed cash flow statement for Xos Inc (XOS), presenting both quarterly and annual data with year-over-year changes across operating, investing, and financing activities. It also includes an FAQ section defining key cash flow metrics like operating cash flow, investing cash …

Gaxos.AI Inc (GXAI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Gaxos.AI Inc (GXAI) shareholder structure, detailing major shareholders and institutional holdings. It lists top individual and institutional investors and breaks down shareholder types by proportion, alongside a history of institutional shareholding over various reporting periods.

Xos Inc (XOS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Xos Inc (XOS), listing major individual and corporate holders and their respective proportions. It also outlines the types of shareholders, including corporations, individual investors, and various funds, and provides a historical overview of institutional shareholding and recent …

Xos Inc (XOS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Xos Inc's (XOS) dividend history and stock split events. It indicates that Xos Inc has not distributed any dividends over the past five years. The company did, however, undergo a 30-to-1 merger-related stock split on December 1, 2023.

Axos Financial: Solid Growth Doesn't Change My Opinion

GXAI|Gaxos.AI Inc|Price:1.060|

Gaxos.AI Inc. (GXAI) is a technology company focused on AI solutions for health, longevity, and entertainment. Their offerings include the Gaxos Gaming platform, which employs AI and NFTs for in-game features, and Gaxos Health, which provides AI-driven personalized wellness strategies. The company's stock information, …

Fifth Third Bancorp Has $1.18 Million Stock Holdings in Axos Financial, Inc $AX

Why Is XOS Stock Up 200% Premarket?

Xos Inc. (XOS) shares surged by 200% premarket after the company unveiled its "Power Hub" series, a mobile power storage and supply solution. This new offering, likened to a "deployable power plant" by CEO Dakota Semler, addresses the critical need for alternative energy sources …

AX|Axos Financial Inc|Price:95.830|Chg%: +0.600

Axos Financial Inc (AX) is trading at $95.83, up 0.63% from the previous close. The company exhibits strong fundamentals and high growth potential, though its valuation is considered fairly valued within the Banking Services industry. Analysts rate it as a "Buy" with a target …

TradingKey

This article provides a detailed quarterly and annual income statement for Gaxos.AI Inc (GXAI), covering various financial metrics from total revenue and operating expenses to net income and earnings per share. It also includes an FAQ section explaining how to interpret the income statement …

GXAI|Gaxos.AI Inc|Price:1.070|Chg%:+0.010

This article provides a detailed stock analysis of Gaxos.AI Inc (GXAI), highlighting its strong fundamentals, high growth potential, and relatively fair valuation within the Software & IT Services industry. Despite a recent weak market performance, the company's revenue has grown significantly, and institutional ownership …

GSK admits 70,759 shares to trading on London Stock Exchange

GSK plc announced the admission of 70,759 ordinary shares to trading on the London Stock Exchange's Main Market. These shares, part of the GlaxoSmithKline plc Share Save Plan 2022, bring the total number of GSK ordinary shares admitted to trading to 4,316,292,310. The newly …

GSK plc (GSK) adds 70,759 Share Save Plan shares to London listing

GSK plc has announced the admission of 70,759 new ordinary shares to trading on the London Stock Exchange Main Market. These shares are part of the GlaxoSmithKline plc Share Save Plan 2022 and are fully fungible with existing shares. Following this admission, the total …

XOS stock trades around recent lows after revenue growth and wider loss in 2024

XOS, a small-cap electric truck manufacturer, saw its stock trading around recent lows after reporting its 2023 financial results. The company achieved $39.7 million in net sales, an increase from 2022, but still posted a significant net loss of $61.0 million, albeit slightly narrowed …

Gaxos.AI Inc (GXAI) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Gaxos.AI Inc (GXAI), noting its current valuation score of 8.27, ranking 260 out of 485 in the Software & IT Services industry. It highlights the company's P/E ratio of -1.68, which is significantly below its recent high …

Gaxos.AI Inc (GXAI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Gaxos.AI Inc (GXAI), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 24, 2026, the stock's price momentum score is 3.24, ranking 452 out of 485 in its …

Xos Inc(XOS) Stock Options Chain | Quotes & News

The document provides information related to Xos Inc (XOS) stock options chain, including quotes and news. Further details about these aspects would be available within the complete document, aimed at investors tracking XOS performance and related market activities.

Axos Financial (AX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Axos Financial (AX) is projected to report a year-over-year increase in earnings per share (EPS) of 10.8% and revenue growth of 15.9% for the quarter ending June 2026. The company currently has a positive Earnings ESP of +1.28% and a Zacks Rank of #2, …

GSK: Glaxosmithkline plc - ADR Latest Stock Price, Analysis, News and Trading Ideas

This page provides the latest stock price, analysis, news, and trading ideas for Glaxosmithkline plc (GSK) ADR. It includes current market data, financial fundamentals such as market cap, PE ratio, and EPS, and recent news headlines related to GSK's drug approvals and developments. The …

Axos Financial (AX) Expected to Announce Quarterly Earnings on Thursday

GSK (GSK) Q4 2024 earnings summary

GSK announced strong Q4 2024 results with 8% sales growth to over GBP 31.4 billion, driven by specialty medicines and vaccines. Core operating profit increased by 13%, and core EPS rose by 12% to 159.3p, leading to a dividend increase and a new GBP …

GSK (NYSE: GSK) gains early FDA approval for ROS1 lung cancer therapy

GSK has received early FDA approval for Jideytro (zidesamtinib), a therapy for ROS1-positive non-small cell lung cancer in adult patients who have previously used a ROS1 kinase inhibitor. This approval, based on the ARROS-1 trial showing a 44% objective response rate, comes ahead of …

Axos Financial (AX) Could Be 12% Undervalued Following Its Recent Share Price Run

Axos Financial (AX) appears to be 12% undervalued based on a fair value of $111 per share, despite a recent 10.62% increase in its share price over the last month. The valuation is driven by detailed forecasts pointing to benefits from the shift to …

By mid-2027, analysts expect £6,000 in GSK shares to be worth…

Analysts predict that a £6,000 investment in GSK (LSE: GSK) shares could grow to over £6,700 within 12 months, and nearly £6,900 with dividends. Despite recent stagnation and some setbacks like the halt of a key drug development, the company's low valuation and the …

GSK Unveils New Data on Long-Acting HIV Treatments Ahead of AIDS Conference

GSK PLC (NYSE: GSK) announced new data from its subsidiary ViiV Healthcare regarding long-acting HIV treatments, to be presented at the 26th International AIDS Conference. The studies include findings on two-drug and long-acting injectable regimens, aiming to advance HIV treatment options. GSK's current P/E …

GSK plc Stock (GSK) Closed Down by 3.17% on Jul 20: Facts Behind the Movement

GSK plc (GSK) stock fell by 3.17% on July 20, driven by renewed concerns over the Zantac litigation, heightened competition in vaccine markets, rising R&D costs, and broader regulatory scrutiny in the healthcare sector. Technical indicators suggest potential selling pressure, while analysts have adjusted …

EMA reviews GSK (NYSE: GSK) plan for 1-dose Bexsero meningitis B booster

GSK has announced that the European Medicines Agency (EMA) has accepted its submission to update the label for Bexsero to include a single-dose booster for individuals aged 10 years and older who were previously vaccinated. This proposed booster aims to help reduce the burden …

GSK falls Monday, underperforms market

Shares of GSK PLC (GSK) fell on Monday, sliding 1.80% to £18.82, underperforming the broader market as the FTSE 100 Index also declined. The company's stock closed significantly below its 52-week high.

Bessemer Group Inc. Purchases 19,637 Shares of Axos Financial, Inc $AX

Bessemer Group Inc. increased its stake in Axos Financial (NYSE:AX) by 30.3% in the first quarter, acquiring an additional 19,637 shares to own a total of 84,354 shares worth approximately $7.18 million. Institutional investors collectively own 83.79% of the company, while insiders hold 4.85%. …

GSK: EMA Accepts Filing For Bexsero Single-Dose Booster In Adolescents

(RTTNews) - GSK plc (GSK) announced that the European Medicines Agency (EMA) has accepted its submission to update the label for Bexsero, aiming to include a single-dose booster for individuals aged 10 years and older who were previously vaccinated in infancy. Invasive meningococcal disease …

Avoiding Lag: Real-Time Signals in (GSK) Movement

This article provides real-time signal analysis for GSK, highlighting weak near-term sentiment but strong long-term projections. It offers three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels …

Xos, Inc. (XOS) director disposes 12,476 shares in 10b5-1 plan

Xos, Inc. director Dietmar Ostermann disposed of a total of 12,476 shares of Common Stock between July 15-17, 2026, under a Rule 10b5-1 trading plan adopted in September 2025. The shares were sold at weighted average prices ranging from $2.11 to $2.34 per share. …

Xos, Inc. (XOS) director reports 3 stock sale transactions under 10b5-1 plan

Xos, Inc. director Michael Paul Richardson reported three dispositions of common stock between July 15-17, 2026, totaling 9,356 shares. These sales were executed under a Rule 10b5-1 trading plan adopted in September 2025, with weighted average sale prices ranging from $2.1487 to $2.3067 per …

Form 4 Xos Inc For: 17 July By Investing.com

This article announces the filing of Form 4 for Xos Inc. for July 17th. It is a brief report from Investing.com, accompanied by various market data and other news headlines.

Xos, Inc. (XOS) director trades 7,500 shares in Rule 10b5-1 plan

Xos, Inc. director Alice Yake disposed of 7,500 shares of common stock across three days, from July 15-17, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at weighted average prices between $2.1481 and $2.3042 per share. Following these transactions, Yake …

GSK (GSK) Stock Price, News & Analysis $GSK

GSK (GlaxoSmithKline plc) is a London-headquartered pharmaceutical company focused on prescription medicines, vaccines, and specialty treatments. The company's stock currently has a "Hold" consensus rating from analysts, with a price target of $53.00, approximately 5.5% higher than its current trading price. Recent news indicates …